Literature DB >> 31040094

Acute onset autoimmune hepatitis: Clinical presentation and treatment outcomes.

Abdulrahman A Aljumah1, Hamad Al-Ashgar2, Hind Fallatah3, Ali Albenmousa4.   

Abstract

INTRODUCTION AND AIM: Autoimmune hepatitis (AIH) may present acutely, which can rapidly progress to fulminant type. This pattern has been described worldwide but is generally under-reported. We aim to describe the clinical presentation and treatment outcomes of patients with acute onset AIH.
MATERIALS AND METHODS: A multicenter retrospective cohort study of patients with acute onset AIH. Clinical, biochemical, and histological data were analyzed and the outcomes were reported.
RESULTS: Seventy patients were included. The mean age was 33.8±1.5 years and 58.6% were female. Upon initial presentation, 94% had jaundice, 44% had fatigue, 31% had pruritus, and 29% had abdominal pain. Biochemical analysis revealed elevated alanine transaminase (733±463.6), aspartate transaminase (699±423), and total bilirubin (210±181.8). Antinuclear antibody (ANA) was positive in 61% of patients, anti-smooth muscle antibody (ASMA) in 69%, and both in 31%; immunoglobulin G (IgG) was elevated in 86% of patients. Advanced fibrosis was found in 39%. Complete remission was achieved in 74.3%, two patients required liver transplants and six died. No specific biomarkers were identified as predictive of remission; however, advanced age was associated with poor prognosis.
CONCLUSION: Acute onset AIH is a disease that requires early diagnosis and management. We confirmed that elevated transaminases are the hallmark of biochemical presentation of acute AIH. High IgG, ANA and ASMA are typically present in such patients upon presentation, however, their absence does not totally exclude the diagnosis. Initial response to treatment was excellent; however, the long-term mortality was higher than the general patient population.
Copyright © 2019 Fundación Clínica Médica Sur, A.C. Published by Elsevier España, S.L.U. All rights reserved.

Entities:  

Keywords:  Auto-antibodies; Fibrosis; Liver failure; Steroids; Transaminase

Year:  2019        PMID: 31040094     DOI: 10.1016/j.aohep.2018.09.001

Source DB:  PubMed          Journal:  Ann Hepatol        ISSN: 1665-2681            Impact factor:   2.400


  3 in total

1.  Presence of Serum Antinuclear Antibodies Does Not Impact Outcomes in HBV-Related Acute-on-Chronic Liver Failure.

Authors:  Lin Lin; Bin Lin; Qing Lan; Longgen Liu; Jianchun Lu; Xiujun Zhang; Shuqin Zheng; Yuan Xue
Journal:  Can J Gastroenterol Hepatol       Date:  2022-02-18

2.  Analysis of Targeted Post-operative Nursing Outcome in 1246 Patients with Percutaneous Transhepatic Biliary Drainage.

Authors:  Xiuchun Yang; Yuelan Qin; Wei Mo; Hua Xiang; Zhichao Liu; Jianhua Long; Bin Xiang
Journal:  Front Surg       Date:  2022-04-27

Review 3.  Pathogenesis of Autoimmune Hepatitis-Cellular and Molecular Mechanisms.

Authors:  Claudia Sirbe; Gelu Simu; Iulia Szabo; Alina Grama; Tudor Lucian Pop
Journal:  Int J Mol Sci       Date:  2021-12-17       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.